4D Biomaterials

4D Medicine Limited is a pioneering company in the medical technology sector, focusing on the development and commercialization of advanced resorbable biomaterials and implantable medical devices. The company operates through two wholly owned subsidiaries, each dedicated to specific aspects of research, development, and bringing new medical solutions to market.

The core technology of 4D Medicine revolves around a patented resorbable photocurable resin, which is based on unique polycarbonate urethane chemistry. This innovative material is the result of 15 years of rigorous academic research conducted at leading universities in the UK. The technology aims to address and overcome the limitations and clinical performance issues associated with current resorbable biomaterials, such as Polylactic Acid (PLA), Polycaprolactone (PCL), and Poly Lactic co Glycolic Acid (PLGA).

Current resorbable biomaterials have several drawbacks, including brittleness leading to early device failure, poor degradation profiles causing bulk erosion and fragmentation, and degradation by-products that result in pain and local inflammatory responses. Additionally, design constraints of these materials often lead to compromised device geometries. 4D Medicine's technology promises to eliminate these issues, offering a resorbable biomaterial suitable for a wide range of implantable medical device applications.

The company primarily targets the US medical device market, the largest in the world, and is actively working towards obtaining regulatory clearance for its primary medical device. This step is crucial for demonstrating the material's acceptability and effectiveness in medical applications. By doing so, 4D Medicine aims to drive innovation in biomaterials and significantly improve patient outcomes.

4D Medicine's business model involves extensive research and development, followed by commercialization of their patented technology through their subsidiaries. Revenue is generated through the sale of their advanced biomaterials and medical devices, as well as potential licensing agreements and partnerships with other medical device manufacturers.

Keywords: resorbable biomaterials, implantable devices, medical technology, polycarbonate urethane, innovation, patient outcomes, US market, regulatory clearance, commercialization, research and development.